All studies
AuthorisedTherapeutic confirmatory (Phase III)Interventional

Efficacy and safety of zenagamtide s.c. once weekly compared to semaglutide s.c. once weekly at higher dose levels in participants with type 2 diabetes inadequately controlled on metformin, SGLT2i, or both (AMBITION 3)

This clinical trial is testing a new medicine called zenagamtide for adults living with type 2 diabetes. It is designed for people whose blood sugar levels remain too high, even though they already take standard daily diabetes tablets, such as metformin, an SGLT2 inhibitor, or both. Researchers are comparing zenagamtide against semaglutide, an established once-weekly diabetes injection, given at higher doses. The main aim is to see how well zenagamtide reduces average blood sugar levels over time (measured by an HbA1c test). The trial will also monitor other important health measures, including weight loss, blood pressure, and cholesterol levels. Taking part helps doctors understand if this new treatment is safe and whether it could provide a more effective long-term option for people managing type 2 diabetes.

At a glance

Status
Authorised
Phase
Therapeutic confirmatory (Phase III)
Sponsor
Novo Nordisk A/S
Enrolment target
302
Start
23 Oct 2026

What is this study about?

Type 2 diabetes is a lifelong condition where the body struggles to keep blood sugar at a healthy level. Over time, high blood sugar can damage blood vessels and lead to complications with the heart, kidneys, and eyes. Many people start managing their condition with lifestyle changes and tablets such as metformin. However, because diabetes can change over time, these tablets may eventually stop working as well as they once did, meaning new treatments are needed.

This study, called AMBITION 3, is a Phase 3 trial testing an experimental medicine called zenagamtide. It works similarly to natural gut hormones that help the body release insulin after eating and reduce appetite. In this trial, zenagamtide is being compared with semaglutide, a treatment already used for diabetes, to see which medicine performs better when given at higher doses.

Both medicines are given once a week as a gentle injection just under the skin. By comparing them side by side, researchers hope to see whether zenagamtide is better at bringing down blood sugar levels. They are also checking whether it helps people lose excess weight and improves other markers of heart health, such as blood pressure and cholesterol.

Key takeaways

  • The trial compares a new weekly injection (zenagamtide) with an existing medicine (semaglutide).
  • It is designed for adults with type 2 diabetes whose current tablets are no longer enough.
  • The main aim is to lower long-term blood sugar levels (HbA1c).
  • Researchers will also track improvements in body weight, cholesterol, and blood pressure.
  • Participation is entirely voluntary and includes regular, specialist health check-ups.

Who may be eligible?

This trial is open to men and women aged 18 and older who have been diagnosed with type 2 diabetes. To be considered, your blood sugar levels must still be higher than your target range, despite taking regular diabetes tablets such as metformin, an SGLT2 inhibitor (like dapagliflozin or empagliflozin), or a combination of both.

You might not be able to join if you have type 1 diabetes, serious kidney or liver problems, or a history of certain digestive conditions. Women who are pregnant, planning a pregnancy, or breastfeeding are also usually unable to take part for safety reasons.

The study team will review your full medical history, run routine blood tests, and check your current medications to confirm whether the trial is a safe and suitable match for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I have been diagnosed with type 2 diabetes.
  3. I currently take metformin, an SGLT2 inhibitor, or both.
  4. My blood sugar levels are still higher than my target range.
  5. I am willing and able to attend regular clinic check-ups.
Answer every question to see your result.

What does participation involve?

If you decide to take part, you will be in the study for several months. You will be randomly assigned by a computer to receive either zenagamtide or semaglutide. Because the study is 'blinded' to keep the results fair, you may also receive a dummy injection (placebo) so neither you nor the doctors know which active medicine you are receiving.

You will learn how to give yourself a small weekly injection under the skin using a simple pen device, similar to standard insulin or diabetes pens. Throughout the study, you will visit a local clinic regularly for health check-ups. At these appointments, the team will check your blood pressure, measure your weight, and take blood samples to measure your HbA1c (average blood sugar) and cholesterol.

You will also have regular contact with the study nurses to talk about any symptoms and track your general wellbeing.

Potential risks and benefits

Taking part offers the benefit of frequent, expert medical care and close monitoring of your diabetes throughout the study. You may also find that the study medicine helps improve your blood sugar levels and supports weight loss. However, as with any medicine, there are possible side effects. Drugs of this type can cause mild to moderate tummy troubles, such as feeling sick, diarrhoea, or constipation, especially when first starting. There is also a chance the treatment will not work as well for you as hoped. Taking part is completely voluntary, and you are free to leave the trial at any point without it affecting your usual NHS care.

Locations (7)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Portugal
  • —
    Unverified
    Bulgaria
  • —
    Unverified
    Czechia
  • —
    Unverified
    Italy
  • —
    Unverified
    Denmark
  • —
    Unverified
    Slovakia
  • —
    Unverified
    Greece

Common questions

What is an HbA1c test?

An HbA1c test is a simple blood test that shows your average blood sugar levels over the past two to three months. It gives doctors a reliable picture of how well your diabetes is being managed.

Will I have to pay to take part?

No. The study medication, clinic visits, and tests are provided free of charge. In most cases, travel expenses to and from the clinic are also covered.

Do I have to stop taking my current diabetes tablets?

In most cases, you will continue taking your background tablets, such as metformin, alongside the study injection. The trial doctor will give you exact instructions on how to take your medications.

What happens if I change my mind?

You can leave the study at any time, for any reason. Your decision will not change your relationship with your regular GP or affect the standard care you receive.

Will I know which medicine I am getting?

No. This is a blinded trial, meaning neither you nor your study doctor will know whether you are taking zenagamtide or semaglutide. This is standard practise to make sure the results are accurate and unbiased.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.